$$ D E T O N A T I O N $$

From his Beijing office, Genesis Director Dr. Shaohua Tan stated: "Additional candidate partner companies are being screened in China by the Genesis team. Our goal is to sign up 4-6 new partners in the next 12-18 months. Each could provide Genesis with substantial profits and assets enhancement.
"However, this is a challenging and risk-laden process. Followers of the Genesis business model must understand that, until the Chinese partner company officially reaches public company status and files its initial Form 8-K, a high degree of risk exists that the partner may not ever attain that status. While the receipt of such stock is contractual, Genesis still recognizes that such compensation is conditional on performance and specific deliverables," reminded Dr. Tan.

released a letter from its Chief Executive Officer and Board of Directors that summarizes the Company's historic success recorded in fiscal year 2006 and forecasts even stronger performance in the future. The communication states that profits reaching $20 million and assets of $30 million are considered possible, based on current performance and trends.
The complete letter is accessible at www.genesis-china.net/letters.html, on the Genesis website, or by email and regular mail upon requests made to the Corporate Headquarters in Boca Raton, Florida.
Among the key points of the letter are:

-- For fiscal year 2006, the Company reported net income of $2.9
   million and assets of $7.2 million, making the year its most
   successful in its history. This equated to net income of $0.03
   per common share, fully diluted, and a positive increase,
   year-to-year, of $6.6 million. Its revenues reached $6,750,229 as
   compared to $154,580 for the year ended September 30, 2005, an
   increase of $6,595,649 or 4267%.

-- From its evolving Genesis Equity Partners program, an umbrella of
   limited liability subsidiaries, the Company believes that it
   could generate at least $2 million in profits from each Chinese
   partner company. Such projected profits are based on the first
   graduate of the revitalized program, Lotus Pharmaceuticals, Inc.
    (LTUS : lotus pharm inc comNews , chart , profile , moreLast: 1.75-0.25-12.50%10:00am 03/07/2007Delayed quote dataAdd to portfolioAnalyst Create alertInsiderDiscussFinancials Sponsored by:LTUS1.75,
     -0.25,
     -12.5%
     )
    that actually produced profits far exceeding these
   levels. Genesis projects it could add as many as six new partners
   to its existing four contracts, and envisions profits possibly
   reaching $20 million and assets of $30 million or more.

-- Management holds that forming a turnkey operation coupled with
   sustainability and repeated success should convince the U.S.
   investment community that Genesis is for real and deserves the
   consistent support that would limit the current vagaries and
   uncertainties of the Bulletin Board market place. The letter
   concludes by stating that "management has reached the point that
   it welcomes being judged by results and not promises."

"With appropriate financing, our strategy is that, by acquiring these two companies, Lotus will establish itself as one of the major pharmaceutical companies with much expanded marketing channels and a good range of products, plus a superb R&D capability. The revenue expansion comes from selling a range of both high turn-around products and new and effective drugs through the much-expanded marketing channels. The profit margin improvement comes from selling more self-manufactured drugs. These are the key strategies for a pharmaceutical company to win in China under the current market conditions.
"To summarize our post-acquisition profile, Lotus could have near-term revenues of about $142 Million, with a 10% profit margin. More importantly, it would put Lotus on the fast track to leverage on the synergy of the companies. And we conservatively forecast 20% growth in revenue for the coming years, with an average margin of about 12-15% after acquisitions. This would place Lotus amongst the top 100 pharmaceutical companies in China," Dr. Liu concluded.

"We now have five partner companies in various stages of our program. With the exception of our newest partner, each of these partners has a U.S. corporate identity: (1) Lotus Pharmaceuticals, (2) Gold Horse International, (3) China Environmental Technologies, and (4) Oriental Health Beverages.

"Our fifth partner company, the steel products enterprise, is larger than previous clients and offers Genesis a compelling opportunity for shareholder value creation. With China\'s unrelenting growth and construction, our steel products partner is well poised for a bright future. We shall report as this company moves through the GEP program, as we will with Gold Horse and our two other identified partner companies. We anticipate signing additional partner companies in the near future," Dr. Tan concluded.

About Genesis Technology Group, Inc.

Genesis Technology Group, Inc. (d/b/a Genesis China and GTEC) is a U.S. public company that earns, enhances and markets equity positions in small to mid-sized Chinese enterprises. Commitment, dedication, and expertise are the key components to the Genesis "Mission Statement." It has created a successful profit center by incubating Chinese companies in a wide range of sectors, creating so-coined "partner companies." Genesis makes a long-term commitment with management consultation, board of directors composition, creation and implementation of successful business models, which include expansion of markets in China and abroad. To help drive the success and profitability of these operations, Genesis provides resources and proficiency to maximize partners\' leadership potential in China and attempts to increase high-margin, predictable earnings. For more information, visit www.Genesis-China.net.

Safe Harbor Statement and Disclaimer

Certain statements set forth in this press release constitute "forward-looking statements". Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply Future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company\'s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company\'s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company\'s limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company\'s business and financial results is included in the Company\'s filings, available via the United States Securities and Exchange Commission. The capital and growth program, the Company\'s central profit center, has specific risks and liabilities. Followers of our business model must understand that, until the Chinese partner company officially reaches public company status and files its initial Form 8-K, a high degree of risk exists that the partner may not ever attain that status. While receipt of a significant equity position in these companies is contractual, Genesis still recognizes that such compensation is conditional on performance and specific deliverables.

CONTACT: Genesis Technology Group, Inc.
Kenneth L. Clinton, President
(561) 988-9880
Fax: (561) 988-9890
info@Genesis-China.net
7900 Glades Road, Suite 420
Boca Raton, Florida 33434
United States of America

Dr. Shaohua Tan, who negotiated the contract with the steel products company, serves as the Genesis Director at its Beijing executive offices. Dr. Tan commented: "The GEP private-to-public program is a challenging process, requiring committed Chinese partners and experienced U.S. guidance. Coupling Genesis' skill base with exciting, high-growth Chinese companies can produce benefits for all parties.
"We now have five partner companies in various stages of our program. With the exception of our newest partner, each of these partners has a U.S. corporate identity: (1) Lotus Pharmaceuticals, (2) Gold Horse International, (3) China Environmental Technologies, and (4) Oriental Health Beverages.
"Our fifth partner company, the steel products enterprise, is larger than previous clients and offers Genesis a compelling opportunity for shareholder value creation. With China's unrelenting growth and construction, our steel products partner is well poised for a bright future. We shall report as this company moves through the GEP program, as we will with Gold Horse and our two other identified partner companies. We anticipate signing additional partner companies in the near future," Dr. Tan concluded.